托吡酯治疗苯丙胺和甲基苯丙胺使用障碍的疗效:一项随机对照试验。

Q2 Medicine
Amirali Moghaddam Sadegh, Masoumeh Nazarinasab, Forouzan Behrouzian, Hamzeh Rostami, Masoumeh Mehrabi
{"title":"托吡酯治疗苯丙胺和甲基苯丙胺使用障碍的疗效:一项随机对照试验。","authors":"Amirali Moghaddam Sadegh,&nbsp;Masoumeh Nazarinasab,&nbsp;Forouzan Behrouzian,&nbsp;Hamzeh Rostami,&nbsp;Masoumeh Mehrabi","doi":"10.18502/ijps.v18i4.13624","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Limited studies have yet evaluated the effectiveness of topiramate in the treatment of amphetamine and methamphetamine addiction. Therefore, the aim of this study was to investigate the effectiveness of topiramate in the treatment of patients with this disorder. <b>Methods:</b> In this randomized, double-blind, placebo-controlled clinical trial, 52 patients with amphetamine and methamphetamine use disorder, within the age range of 16-60 years, were randomly divided into an intervention group (n = 26) and a placebo group (n = 26). The intervention group was treated with topiramate tablets with a starting dose of 50 mg, which was gradually increased to the target dose of 200 mg. The control group was treated with placebo. The duration of drug intervention in this clinical trial was 12 weeks, and all participants were evaluated before the intervention and 2, 4, 6, 8, 10, and 12 weeks after beginning the intervention. The Beck Depression Inventory, drug use temptation questionnaire, urine test, and side effects questionnaire were used as outcome measures to assess the patients. The data were analyzed using chi-square, independent t-test, and analysis of variance with repeated measurements. <b>Results:</b> There was no significant difference between the intervention and placebo groups in depression at the beginning of the treatment and at the 4<sup>th</sup>, 8<sup>th</sup>, and 12<sup>th</sup> weeks after the intervention (P > 0.05). The urine test also showed no significant difference between the two groups at any of the evaluation stages (P > 0.05). Although there was no significant difference between the two groups in the drug use temptation results at the beginning and the 2<sup>nd</sup>, 4<sup>th</sup> and 6<sup>th</sup> weeks (P > 0.05), the level of drug temptation in the intervention group was significantly lower than the placebo group in the 8<sup>th</sup>, 10<sup>th</sup>, and 12<sup>th</sup> weeks (P < 0.05). <b>Conclusion:</b> Topiramate can be effective in reducing the desire to use amphetamine and methamphetamine. However, further studies are needed to confirm these results.</p>","PeriodicalId":38866,"journal":{"name":"Iranian Journal of Psychiatry","volume":"18 4","pages":"371-379"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/63/IJPS-18-371.PMC10594000.pdf","citationCount":"0","resultStr":"{\"title\":\"The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial.\",\"authors\":\"Amirali Moghaddam Sadegh,&nbsp;Masoumeh Nazarinasab,&nbsp;Forouzan Behrouzian,&nbsp;Hamzeh Rostami,&nbsp;Masoumeh Mehrabi\",\"doi\":\"10.18502/ijps.v18i4.13624\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> Limited studies have yet evaluated the effectiveness of topiramate in the treatment of amphetamine and methamphetamine addiction. Therefore, the aim of this study was to investigate the effectiveness of topiramate in the treatment of patients with this disorder. <b>Methods:</b> In this randomized, double-blind, placebo-controlled clinical trial, 52 patients with amphetamine and methamphetamine use disorder, within the age range of 16-60 years, were randomly divided into an intervention group (n = 26) and a placebo group (n = 26). The intervention group was treated with topiramate tablets with a starting dose of 50 mg, which was gradually increased to the target dose of 200 mg. The control group was treated with placebo. The duration of drug intervention in this clinical trial was 12 weeks, and all participants were evaluated before the intervention and 2, 4, 6, 8, 10, and 12 weeks after beginning the intervention. The Beck Depression Inventory, drug use temptation questionnaire, urine test, and side effects questionnaire were used as outcome measures to assess the patients. The data were analyzed using chi-square, independent t-test, and analysis of variance with repeated measurements. <b>Results:</b> There was no significant difference between the intervention and placebo groups in depression at the beginning of the treatment and at the 4<sup>th</sup>, 8<sup>th</sup>, and 12<sup>th</sup> weeks after the intervention (P > 0.05). The urine test also showed no significant difference between the two groups at any of the evaluation stages (P > 0.05). Although there was no significant difference between the two groups in the drug use temptation results at the beginning and the 2<sup>nd</sup>, 4<sup>th</sup> and 6<sup>th</sup> weeks (P > 0.05), the level of drug temptation in the intervention group was significantly lower than the placebo group in the 8<sup>th</sup>, 10<sup>th</sup>, and 12<sup>th</sup> weeks (P < 0.05). <b>Conclusion:</b> Topiramate can be effective in reducing the desire to use amphetamine and methamphetamine. However, further studies are needed to confirm these results.</p>\",\"PeriodicalId\":38866,\"journal\":{\"name\":\"Iranian Journal of Psychiatry\",\"volume\":\"18 4\",\"pages\":\"371-379\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/63/IJPS-18-371.PMC10594000.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/ijps.v18i4.13624\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijps.v18i4.13624","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:目前评估托吡酯治疗苯丙胺和甲基苯丙胺成瘾的有效性的研究有限。因此,本研究的目的是研究托吡酯治疗该疾病患者的有效性。方法:在这项随机、双盲、安慰剂对照的临床试验中,52名年龄在16-60岁之间的苯丙胺和甲基苯丙胺使用障碍患者被随机分为干预组(n=26)和安慰剂组(n=6)。干预组用托吡酯片治疗,起始剂量为50 mg,逐渐增加到200 mg的目标剂量。对照组用安慰剂治疗。本临床试验中药物干预的持续时间为12周,所有参与者在干预前和干预开始后2、4、6、8、10和12周进行评估。使用Beck抑郁量表、药物使用诱惑问卷、尿检和副作用问卷作为评估患者的结果指标。使用卡方、独立t检验和重复测量的方差分析对数据进行分析。结果:干预组和安慰剂组在抑郁症治疗开始时与治疗后第4、8、10、10、11、12、12、13、13、14、14、16、17、17、18、18、19、19、21、21、22、21、23、21、24、23、23、24、24、25、24、26,尿检也显示两组在任何评估阶段均无显著差异(P>0.05)。尽管两组在干预开始时和第2、4、6周的药物使用诱惑结果没有显著差异(P>0.05),在第8、10和12周,干预组的药物诱惑水平显著低于安慰剂组(P<0.05)。结论:托吡酯可有效降低苯丙胺和甲基苯丙胺的使用欲望。然而,还需要进一步的研究来证实这些结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial.

The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial.

Objective: Limited studies have yet evaluated the effectiveness of topiramate in the treatment of amphetamine and methamphetamine addiction. Therefore, the aim of this study was to investigate the effectiveness of topiramate in the treatment of patients with this disorder. Methods: In this randomized, double-blind, placebo-controlled clinical trial, 52 patients with amphetamine and methamphetamine use disorder, within the age range of 16-60 years, were randomly divided into an intervention group (n = 26) and a placebo group (n = 26). The intervention group was treated with topiramate tablets with a starting dose of 50 mg, which was gradually increased to the target dose of 200 mg. The control group was treated with placebo. The duration of drug intervention in this clinical trial was 12 weeks, and all participants were evaluated before the intervention and 2, 4, 6, 8, 10, and 12 weeks after beginning the intervention. The Beck Depression Inventory, drug use temptation questionnaire, urine test, and side effects questionnaire were used as outcome measures to assess the patients. The data were analyzed using chi-square, independent t-test, and analysis of variance with repeated measurements. Results: There was no significant difference between the intervention and placebo groups in depression at the beginning of the treatment and at the 4th, 8th, and 12th weeks after the intervention (P > 0.05). The urine test also showed no significant difference between the two groups at any of the evaluation stages (P > 0.05). Although there was no significant difference between the two groups in the drug use temptation results at the beginning and the 2nd, 4th and 6th weeks (P > 0.05), the level of drug temptation in the intervention group was significantly lower than the placebo group in the 8th, 10th, and 12th weeks (P < 0.05). Conclusion: Topiramate can be effective in reducing the desire to use amphetamine and methamphetamine. However, further studies are needed to confirm these results.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Iranian Journal of Psychiatry
Iranian Journal of Psychiatry Medicine-Psychiatry and Mental Health
CiteScore
4.00
自引率
0.00%
发文量
42
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信